Audentes Therapeutics, Inc. (BOLD) [Rocket]

In millions, except per share items	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
	10-K	10-K	10-K	10-K	10-K
Revenues	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	30.0	17.3	11.3	6.5	1.7
General and administrative	30.0	17.3	11.3	6.5	1.7
Research and development	104.4	75.9	48.8	20.2	9.3
EBITDA [+]	-128.8	-89.8	-58.4	-26.6	-10.9
EBITDA growth	43.4%	53.7%	119.9%	143.3%
Depreciation and amortization	5.6	3.4	1.6	0.2	0.0
EBIT [+]	-134.4	-93.2	-60.0	-26.7	-11.0
EBIT growth	44.2%	55.2%	124.7%	144.1%
Interest income	6.0	0.8	0.5	0.2	0.0
Interest income	6.0	0.8	0.5	0.2	0.0
Other income (expense), net	-0.5	-0.1	-0.1	0.0	0.1
Pre-tax income	-128.8	-92.5	-59.7	-26.5	-10.8
Income taxes	0.0	-2.2	0.0	0.0	0.0
Tax rate	0.0%	2.4%	0.0%	0.0%	0.0%
Net income	-128.8	-90.2	-59.7	-26.5	-10.8

Basic EPS [+]	($3.40)	($3.40)	($5.59)	($23.03)	($21.56)
Growth	0.3%	-39.3%	-75.7%	6.8%
Diluted EPS [+]	($3.40)	($3.40)	($5.59)	($23.03)	($21.56)
Growth	0.3%	-39.3%	-75.7%	6.8%

Shares outstanding (basic) [+]	37.8	26.6	10.7	1.1	0.5
Growth	42.4%	149.0%	829.1%	129.0%
Shares outstanding (diluted) [+]	37.8	26.6	10.7	1.1	0.5
Growth	42.4%	149.0%	829.1%	129.0%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.